Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer

Breast Cancer Research and Treatment

Volumn 153, Issue 1, 2015, Pages 21-30

  Forghani, Parvin ^a   Waller, Edmund K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

4T1; Breast cancer; Mice; Myeloid derived suppressor cells (MDSC); Poly (I: C)

Indexed keywords

PHOSPHATE BUFFERED SALINE; POLYINOSINIC POLYCYTIDYLIC ACID; MEMBRANE ANTIGEN; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 3;

4T1 LUC CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL MONITORING; BIOLUMINESCENCE; BONE MARROW CELL; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MODEL; CELL ACTIVITY; CELL FUNCTION; CELLULAR IMMUNITY; CONTROLLED STUDY; COULTER COUNTER; FEMALE; FLOW CYTOMETRY; IMMUNOMODULATION; LEUKOCYTE COUNT; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; ANIMAL; BREAST TUMOR; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; PATHOLOGY; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; ANTIGENS, SURFACE; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MYELOID CELLS; POLY I-C; REACTIVE OXYGEN SPECIES; TH1 CELLS; TOLL-LIKE RECEPTOR 3; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84939251957     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3508-y     Document Type: Article

References (38)

1. Zoglmeier C, Bauer H, Norenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C (2011) CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res 17(7):1765–1775
2. Finke J (2011) MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic. Inter Immunopharmacol 11:856
3. Nakamura H, Horai Y, Suzuki T, Okada A, Ichinose K, Yamasaki S, Koji T, Kawakami A (2013) TLR3-mediated apoptosis and activation of phosphorylated Akt in the salivary gland epithelial cells of primary Sjogren’s syndrome patients. Rheumatol Int 33(2):441–450
4. Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE 3rd (2013) Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat 140(1):13–21
5. Harashima N, Inao T, Imamura R, Okano S, Suda T, Harada M (2012) Roles of the PI3 K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother 61(5):667–676
6. Sun R, Zhang Y, Lv Q, Liu B, Jin M, Zhang W, He Q, Deng M, Liu X, Li G et al (2011) Toll-like receptor 3 (TLR3) induces apoptosis via death receptors and mitochondria by up-regulating the transactivating p63 isoform alpha (TAP63alpha). J Biol Chem 286(18):15918–15928
7. Taura M, Fukuda R, Suico MA, Eguma A, Koga T, Shuto T, Sato T, Morino-Koga S, Kai H (2010) TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis. Cancer Sci 101(7):1610–1617
8. Liechtenstein T, Perez-Janices N, Gato M, Caliendo F, Kochan G, Blanco-Luquin I, Van der Jeught K, Arce F, Guerrero-Setas D, Fernandez-Irigoyen J et al (2014) A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget 5(17):7843–7857
9. Ghansah T (2012) A novel strategy for modulation of MDSC to enhance cancer immunotherapy. Oncoimmunology 1(6):984–985
10. Mignot G, Chalmin F, Ladoire S, Rébé C, Ghiringhelli F (2011) Tumor exosome-mediated MDSC activation. Am J pathol 178(3):1403–1405
11. Green TL, Santos MF, Ejaeidi AA, Craft BS, Lewis RE, Cruse JM (2014) Toll-like receptor (TLR) expression of immune system cells from metastatic breast cancer patients with circulating tumor cells. Exp Mol Pathol 97(1):44–48
12. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58(1):49–59
13. Chi N, Tan Z, Ma K, Bao L, Yun Z (2014) Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer. Int J Clin Exp Med 7(10):3181–3192
14. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T (2006) TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 176(8):4894–4901
15. Cheng YS, Xu F (2010) Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther 10(12):1219–1223
16. Forghani P, Khorramizadeh MR, Waller EK (2014) Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer. Cancer Med 3(2):215–224
17. Ray A, Dittel BN (2010) Isolation of mouse peritoneal cavity cells. J Vis Exp 35:1488
18. Forghani P, Harris W, Giver CR, Mirshafiey A, Galipeau J, Waller EK (2013) Properties of immature myeloid progenitors with nitric-oxide-dependent immunosuppressive activity isolated from bone marrow of tumor-free mice. PLoS ONE 8(7):e64837
19. Ostrand-Rosenberg S, Sinha P, Chornoguz O, Ecker C (2012) Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). Cancer Immunol Immunother 61(8):1319–1325
20. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G (2008) Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 181(7):4666–4675
21. Fucikova J, Rozkova D, Ulcova H, Budinsky V, Sochorova K, Pokorna K, Bartunkova J, Spisek R (2011) Poly I: C-activated dendritic cells that were generated in Cell Gro for use in cancer immunotherapy trials. J Trans Med 9:223
22. Verdijk RM, Mutis T, Esendam B, Kamp J, Melief CJ, Brand A, Goulmy E (1999) Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol 163(1):57–61
23. Moller I, Michel K, Frech N, Burger M, Pfeifer D, Frommolt P, Veelken H, Thomas-Kaskel AK (2008) Dendritic cell maturation with poly(I:C)-based versus PGE2-based cytokine combinations results in differential functional characteristics relevant to clinical application. J Immunother 31(5):506–519
24. Nagaraj S, Nelson A, Youn JI, Cheng P, Quiceno D, Gabrilovich DI (2012) Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res 72(4):928–938
25. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F (2007) The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 67(2):585–592
26. Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF et al (2009) The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 119(10):3011–3023
27. Salaun B, Zitvogel L, Asselin-Paturel C, Morel Y, Chemin K, Dubois C, Massacrier C, Conforti R, Chenard MP, Sabourin JC et al (2011) TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res 71(5):1607–1614
28. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S (2009) Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol 85(6):996–1004
29. Conrad E, Resch TK, Gogesch P, Kalinke U, Bechmann I, Bogdan C, Waibler Z (2014) Protection against RNA-induced liver damage by myeloid cells requires type I interferon and IL-1 receptor antagonist in mice. Hepatology 59(4):1555–1563
30. Aranda F, Llopiz D, Diaz-Valdes N, Riezu-Boj JI, Bezunartea J, Ruiz M, Martinez M, Durantez M, Mansilla C, Prieto J et al (2011) Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res 71(9):3214–3224
31. Paone A, Starace D, Galli R, Padula F, De Cesaris P, Filippini A, Ziparo E, Riccioli A (2008) Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 29(7):1334–1342
32. Forte G, Rega A, Morello S, Luciano A, Arra C, Pinto A, Sorrentino R (2012) Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer. J Immunol 188(11):5357–5364
33. Shime H, Kojima A, Maruyama A, Saito Y, Oshiumi H, Matsumoto M, Seya T (2014) Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models. J Innate Immun 6(3):293–305
34. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22(4):275–281
35. Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, Mendez-Huergo SP, Stupirski JC, Mazal D, Osinaga E, Toscano MA et al (2013) Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res 73(3):1107–1117
36. Kovacs-Solyom F, Blasko A, Fajka-Boja R, Katona RL, Vegh L, Novak J, Szebeni GJ, Krenacs L, Uher F, Tubak V et al (2010) Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1. Immunol Lett 127(2):108–118
37. Liu C, Zhang C, Lu H, Cai J, Wang Z, Chen J, Liu F, Wu Z, Liu X, Sun W (2011) Poly(I:C) induce bone marrow precursor cells into myeloid-derived suppressor cells. Mol Cell Biochem 358(1–2):317–323
38. Danilin S, Merkel AR, Johnson JR, Johnson RW, Edwards JR, Sterling JA (2012) Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology 1(9):1484–1494